These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 2579615)

  • 1. Stimulants, urinary catecholamines, and indoleamines in hyperactivity. A comparison of methylphenidate and dextroamphetamine.
    Zametkin AJ; Karoum F; Linnoila M; Rapoport JL; Brown GL; Chuang LW; Wyatt RJ
    Arch Gen Psychiatry; 1985 Mar; 42(3):251-5. PubMed ID: 2579615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of methylphenidate on urinary catecholamine excretion in hyperactivity: a partial replication.
    Zametkin AJ; Hamburger SD
    Biol Psychiatry; 1988 Feb; 23(4):350-6. PubMed ID: 3342265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemoline and urinary excretion of catecholamines and indoleamines in children with attention deficit disorder.
    Zametkin AJ; Linnoila M; Karoum F; Sallee R
    Am J Psychiatry; 1986 Mar; 143(3):359-62. PubMed ID: 2420216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulant drug treatment of hyperactivity: biochemical correlates.
    Elia J; Borcherding BG; Potter WZ; Mefford IN; Rapoport JL; Keysor CS
    Clin Pharmacol Ther; 1990 Jul; 48(1):57-66. PubMed ID: 2196146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary monoamine metabolites in children with minimal brain dysfunction.
    Wender PH; Epstein RS; Kopin IJ; Gordon EK
    Am J Psychiatry; 1971 Apr; 127(10):1411-5. PubMed ID: 5549938
    [No Abstract]   [Full Text] [Related]  

  • 6. Reliability of urinary monoamine and metabolite output measurements in depressed patients.
    Linnoila M; Karoum F; Miller T; Potter WZ
    Am J Psychiatry; 1983 Aug; 140(8):1055-7. PubMed ID: 6191580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hyperactive children with monoamine oxidase inhibitors. II. Plasma and urinary monoamine findings after treatment.
    Zametkin A; Rapoport JL; Murphy DL; Linnoila M; Karoum F; Potter WZ; Ismond D
    Arch Gen Psychiatry; 1985 Oct; 42(10):969-73. PubMed ID: 2412521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Day-to-day intraindividual reliability and interindividual differences in monoamines excretion.
    Curtin F; Walker JP; Schulz P
    J Affect Disord; 1996 Jun; 38(2-3):173-8. PubMed ID: 8791186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary MHPG and HVA excretion in boys with attention deficit disorder and hyperactivity treated with d-amphetamine.
    Shekim WO; Javaid J; Davis JM; Bylund DB
    Biol Psychiatry; 1983 Jun; 18(6):707-14. PubMed ID: 6871304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder.
    Castellanos FX; Elia J; Kruesi MJ; Gulotta CS; Mefford IN; Potter WZ; Ritchie GF; Rapoport JL
    Psychiatry Res; 1994 Jun; 52(3):305-16. PubMed ID: 7527565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary monoamines and monoamine metabolites in subtypes of unipolar depressive disorder and normal controls.
    Roy A; Pickar D; Douillet P; Karoum F; Linnoila M
    Psychol Med; 1986 Aug; 16(3):541-6. PubMed ID: 3763772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary excretion of MHPG and normetanephrine in attention deficit hyperactivity disorder.
    Baker GB; Bornstein RA; Douglass AB; Van Muyden JC; Ashton S; Bazylewich TL
    Mol Chem Neuropathol; 1993; 18(1-2):173-8. PubMed ID: 8466590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biogenic amine/metabolite response during in-flight emergencies.
    Krahenbuhl GS; Harris J; Malchow RD; Stern JR
    Aviat Space Environ Med; 1985 Jun; 56(6):576-80. PubMed ID: 2409957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary catecholamines in attention-deficit hyperactivity disorder with and without comorbid anxiety.
    Pliszka SR; Maas JW; Javors MA; Rogeness GA; Baker J
    J Am Acad Child Adolesc Psychiatry; 1994 Oct; 33(8):1165-73. PubMed ID: 7982867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased urine phenylethylamine after methylphenidate treatment in children with ADHD.
    Kusaga A; Yamashita Y; Koeda T; Hiratani M; Kaneko M; Yamada S; Matsuishi T
    Ann Neurol; 2002 Sep; 52(3):372-4. PubMed ID: 12205654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenfluramine and dextroamphetamine treatment of childhood hyperactivity. Clinical and biochemical findings.
    Donnelly M; Rapoport JL; Potter WZ; Oliver J; Keysor CS; Murphy DL
    Arch Gen Psychiatry; 1989 Mar; 46(3):205-12. PubMed ID: 2645848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Norepinephrine metabolism and clinical response to dextroamphetamine in hyperactive boys.
    Shekim WO; Dekirmenjian H; Chapel JL; Javaid J; Davis JM
    J Pediatr; 1979 Sep; 95(3):389-94. PubMed ID: 469661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dextroamphetamine, catecholamines, and behavior. The effect of dextroamphetamine in retarded children.
    Anton AH; Greer M
    Arch Neurol; 1969 Sep; 21(3):248-52. PubMed ID: 5802455
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of d-amphetamine on urinary metabolites of dopamine and norepinephrine in hyperactive boys.
    Shekim WO; Javaid J; Dekirmenjian H; Chapel JL; Davis JM
    Am J Psychiatry; 1982 Apr; 139(4):485-8. PubMed ID: 7065295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attention deficit disorder symptoms and urine catecholamines.
    Rogeness GA; Maas JW; Javors MA; Macedo CA; Fischer C; Harris WR
    Psychiatry Res; 1989 Mar; 27(3):241-51. PubMed ID: 2469096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.